Pauklin, Priit
Marandi, Toomas
Kals, Mart
Ainla, Tiia
Martinson, Katrin
Eha, Jaan
Kampus, Priit
Funding for this research was provided by:
Eesti Teadusagentuur (PRG435, PRG435, PRG435, PRG435, PRG435)
Article History
Received: 16 February 2023
Accepted: 24 July 2023
First Online: 11 August 2023
Declarations
:
: The study was approved by the Research Ethics Committee of the University ofTartu (341/T-7). The study was conducted in accordance with the Declaration of Helsinki. In accordance with the Estonian Personal Data Protection Act and agreement from the Research Ethics Committee of the University of Tartu, individual informed consent to participate in this study was not needed, because patients were assigned a unique study number by the Health Insurance Fund and non-personalized data was released for analysis.
: Not applicable.
: PP has received lecturing fees from Berlin-Chemie Menarini, Servier, Bayer and support for attending meetings from Abbott Medical. TM has received lecturing fees from AstraZeneca. KM has received lecturing fees from Pfizer. TA has received lecturing and consulting fees from Bayer and support for attending meetings from Bayer, Pfizer and Boehringer Ingelheim. PK has received support for attending of meetings from Abbott Medical. MK and JE have declared no conflict of interest.